Results 221 to 230 of about 2,487,415 (296)

ATP13A2 promoted cell stemness, cisplatin resistance, autophagy, and cell progression of bladder cancer. [PDF]

Front Immunol
Zhu C, Lu J, Zhu B, Liu B, Li G, Guo Y, Guo X, Yin Z.   +7 more
europepmc   +1 more source

Stimuli‐responsive nanostructured hydrogen sulfide donors for enhanced cancer treatments

Smart Molecules, EarlyView.
Three typical kinds of stimuli‐responsive nanostructured hydrogen sulfide (H2S) donors are reviewed. The nanostructures ensure precise delivery of H2S to the lesion site and regulate the release behavior. The H2S‐based gas therapy has been used to synergize with other cancer treatment modalities, achieving enhanced efficacy while reducing side effects.
Yuxuan Lyu, Jiaxuan Zhu, Lei Lei, Qingyang Zhong, Zhao Li, Caihong Lei, Fan Rong, Yin Wang   +7 more
wiley   +1 more source

Exosomal miR-4443 confers cisplatin resistance in breast cancer by inhibiting ferroptosis. [PDF]

Discov Oncol
Wang W, Bai J, Tians F.
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

EBV (LMP1) enhances cisplatin resistance by enhancing degradation of interferon regulatory factor 3. [PDF]

Cell Commun Signal
Li Y, Liu N, Yang C, He S, Luo C, Wang L, Tang M, Luo X, Cao Y, Shang L, Shi F.   +10 more
europepmc   +1 more source

Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma

Smart Molecules, EarlyView.
Photoactivated iridium(III) complexes trigger mitochondrial DNA leakage and Ca²⁺ efflux, simultaneously driving pyroptosis and necroptosis to synergistically enhance immunogenic cell death. This multi‐network cascade promotes dendritic cell maturation and CD8⁺ T cell activation, achieving potent photoimmunotherapy of renal cell carcinoma.
Xin Qin, Meng‐Di Chen, Wenqi Gao, Yiping Wang, Lin‐Qing Liu, Zhen Teng, Tienan Qi, Qiyuan Wang, Yuxuan Wang, Daoxiang Li, Keqiang Yan, Ling Pan, Zhongwei Zhao, Shuo Zhao, Kang‐Nan Wang, Shuai Fu, Nengwang Yu   +16 more
wiley   +1 more source

PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinoma. [PDF]

Discov Oncol
Pan X, Sun X, Xing Y, Zhang Z, Shi M.
europepmc   +1 more source

Advances in research on layered double hydroxides for biomedical applications

Smart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang, Zhiping Zhang, Zhao Wang, Hao Zhang, Yen Leng Pak, Yingying Jing, Yurong Guo, Fang Li, Xiao Wang, Quanxiang Han, Lei Yu, Xuejiao Li, Xing Gao, Jibin Song   +13 more
wiley   +1 more source

Ru3: a novel ruthenium-based compound overcomes cisplatin resistance in non-small cell lung cancer via the E2F2-IGFBP3-GPX4 pathway. [PDF]

Apoptosis
Lu Y, Wu S, Jiang Y, Wang M, Liao X, Zhang J, Xiang J, Yang H, Yu M, Min J, Fu C, Lei Y.   +11 more
europepmc   +1 more source

Engineering metal‐organic framework‐based smart porous nanoplatforms for targeted therapy and theranostic applications

Smart Molecules, EarlyView.
MOFs offer high porosity and tunability for biomedical applications, especially in cancer therapy via ROS generation and targeted delivery. Though toxicity, stability, and scalability remain key clinical challenges. Drug loading in MOFs exceeds 60%–70% with controlled release behavior.
Jagabandhu Bag, Subhasis Banerjee, Sabyasachi Banerjee, Sourav De, S. K. Ashok Kumar, Yan‐Jye Shyong, Subhankar Mukhopadhyay   +6 more
wiley   +1 more source